Portal hypertensive gastropathy (PHG) is a common endoscopic finding in patients of cirrhosis of liver. The cause and pathogenesis of PHG in cirrhotic patients is poorly understood. Some studies showed, association of Helicobacter pylori (H. Pylori) with portal hypertensive gastropathy in cirrhosis of liver, but the evidence is not robust. The aim of this study was to assess the association of H. pylori infection and PHG in patients with cirrhosis of liver. This case control study was conducted in the Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, from April 2016 to August 2018. A total of 230 patients with cirrhosis of liver were included in this study. There were 115 cirrhotic patients with PHG as cases and 115 cirrhotic patients without PHG as controls. Upper gastrointestinal Endoscopy and 13C Urea Breath Test (UBT) was done in both cases and controls. In this study, out of 230 cases, 147 (63.91%) found to have H. pylori infection. Among cirrhotic patients with PHG case, 77 (66.95%) was positive in UBT. Out of these 77 UBT positive cases, 55 had mild PHG whereas 22 cases had severe form of PHG. Among 38 cases of cirrhosis with PHG who had negative UBT, 23 had mild PHG and 15 cases had severe form of PHG. The risk of positive urea breath test was not statistically significant in cirrhotic patients with PHG in comparison with cirrhotic patients without PHG (P=0.337, OR 1.303, 95% CI 0.759-2.235). In this study, statistically significant association was not found between H. Pylori and PHG in cirrhotic patients.
Bangladesh Med J. 2021 May; 50(2) : 21-27
Non-alcoholic fatty liver disease (NAFLD) is considered as a common cause of chronic liver disease. It is potentially progressive towards non-alcoholic steatohepatitis (NASH), hepatic fibrosis, cirrhosis and its complications including hepatocellular carcinoma (HCC). So, the need for predictive factors of NAFLD is important. Among the different serum markers in NAFLD, serum uric acid (SUA) has emerged as a possible predictor of severity of liver damage. This observational cross sectional study was carried out involving 100 patients from the department of gastroenterology, BSMMU, Dhaka, with the intention to determine the association of serum uric acid (SUA) level with non-alcoholic fatty liver disease. Among them, 55 were having NAFLD; and 45 subjects without NAFLD were considered as control. The diagnosis of NAFLD was based on the guidelines for the assessment and management of NAFLD in the Asia-pacific region. Serum uric acid, liver enzymes, glycaemic status, serum lipid profile and anthropometric measurements were compared between NAFLD group & control. The mean age was found 41.34 + 10.88 years in both the groups. Male were 62% & female were 38% among the study population. Forty percent of the study subjects were overweight, 23% were obese and 37% had normal body weight. NAFLD patients had significantly higher serum uric level (6.9 + 0.89 mg/dl) in comparison to non-NAFLD group (4.3 +0.87 mg/dl). The study showed that serum uric acid level was significantly associated with NAFLD. Serum uric acid may be used as a useful additional marker to assess the risk of development of NAFLD in the clinical setting of metabolic syndrome.
BSMMU J 2021; 14(4): 125-131
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.